etoposide IV

Derivatives bearing o-, m-, or p-ferrocenylphenyl groups significantly sensitized ABCB1- and ABCG2-overexpressing cells to chemotherapeutics such as vincristine, mitoxantrone, and doxorubicin, reducing IC50 values by up to 12.7- and 10.3-fold, respectively...Drug combination studies revealed synergistic interactions, particularly in vincristine-, mitoxantrone-, and etoposide-resistant cells (synergy scores: 13.6-17.05). Accumulation assays confirmed ABC transporter inhibition, with (S,Z)-4b and (S,Z)-4d increasing intracellular retention of calcein and pheophorbide A up to 3.4- and 2.9-foldcomparable to those of verapamil and Ko143. Antibody-binding assays further indicated that these hybrids act as substrates of ABCB1 and ABCG2.

Molecular characterization of cancer enabled the identification of potential causal links between tumors with distinct histologies and locations, offering a deeper insight into an atypical clinical scenario.

Following etoposide treatment, PCAF-induced acetylation removes RAD51 from chromatin to facilitate the late-phase HR processes...Our findings suggest that decreased PCAF expression enhances HR efficiency, contributing to drug resistance in tumor cells, and the impact of PCAF on HR is dependent on its acetyltransferase activity. Our results highlight a novel role of PCAF in HR and provide a possible mechanism for tumor development and drug resistance caused by low expression of PCAF.

P2, N=22, Recruiting, Yale University | N=36 --> 22

P2, N=195, Recruiting, Institut Curie | Trial completion date: Sep 2030 --> Mar 2031 | Trial primary completion date: Mar 2030 --> Mar 2031

Pharmacogenomic analysis further confirmed that the expression level of ITM2A was negatively correlated with the sensitivity of etoposide. By establishing the 'immunometabolism-therapeutic response' regulatory axis of ITM2A, this study hopes to provide an innovative theoretical basis for the targeted treatment of TNBC and the precise stratification of immunotherapy.

P1, N=46, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Oct 2024

P2, N=40, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

Here, we found that the transition from cellular senescence to pyroptosis promoted small cell lung cancer (SCLC) recurrence after cisplatin and etoposide treatment. Subsequent inflammatory factors [such as interleukin-1 (IL-1)] released by pyroptosis promoted the acquisition of stem-like properties in CCF-negative senescent cells, ultimately promoting tumor recurrence. We also found that a combination of IL-1 receptor antagonist anakinra with chemotherapy delayed recurrence of SCLC, suggesting previously unidentified therapeutic strategies for SCLC.

Despite radical surgery and systemic chemotherapy with carboplatin and etoposide, the patient developed liver metastases within three months and succumbed to disease progression nine months postoperatively. Multimodal therapy remains the mainstay of treatment, but the overall prognosis is poor. Further investigation into molecular characteristics and targeted therapies is urgently needed.

Patients received either carmustine, etoposide, cytarabine, and melphalan (BEAM); melphalan; or thiotepa, busulfan, and cyclophosphamide (TBC) as conditioning chemotherapy. The reliance on international literature on this topic, combined with the scarcity of Australian-specific studies, underscores the importance of this study and its findings. The low mortality rates found in this study are promising for patients undergoing ASCT for hematological malignancies.

Our proposed method significantly improves the feasibility of testing novel initiators of the T:E gene fusion and can be applied to additional studies investigating mechanisms of gene fusion initiation in prostate and other cancers.

P2, N=60, Not yet recruiting, PrECOG, LLC.

P3, N=660, Recruiting, AstraZeneca | Trial primary completion date: May 2033 --> Nov 2031

P2, N=48, Recruiting, University of Miami | Not yet recruiting --> Recruiting

P2, N=26, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2026 --> Aug 2025

GSN expression was also associated with tumor size, age, and chemotherapy sensitivity for Cisplatin, Docetaxel, Doxorubicin, Etoposide, Gemcitabine, and Vinorelbine. GSN has potential as both a prognostic and therapeutic marker in ER + breast cancer, influencing immune response and drug sensitivity. Its low expression in tumors and survival benefits suggest it can help with risk assessment and treatment decisions.

Among four patients with available follow-up (5-19 months), one died of disease at 5 months, one developed multiple bone metastases by 5 months, while two showed no tumor recurrence or metastatic progression (both were treated with radical cystectomy followed by adjuvant etoposide-cisplatin chemotherapy). This study provides the first integrated clinicopathological and molecular characterization of SmCC with rhabdomyosarcomatous differentiation in the bladder. The presence of SmCC-specific alterations (TP53/RB1/TERT) and absence of ARMS-defining fusions support classification as a unique SmCC subtype with divergent rhabdomyosarcomatous differentiation.

P1, N=47, Recruiting, Boehringer Ingelheim | Trial primary completion date: Aug 2025 --> Dec 2025

This study explores the interaction between Escherichia coli and non-CRC-specific anticancer drugs cyclophosphamide, Cytalon, Nitrol, etoposide, gemcitabine, and methotrexate through bacterial modification. NMR analysis and 3D spheroid disruption demonstrated structural drug alterations postincubation in one of the best-responding drugs. These findings highlight microbial drug transformation as a promising avenue for enhancing chemotherapeutic selectivity and efficacy in colorectal cancer treatment.

P1, N=48, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting

These results showed that curcumin protects kidneys from BEP-induced toxicity by reducing oxidative stress, cell death, and inflammation, and it can be considered a possible option to improve renal complications caused by the BEP chemotherapy regimen.

We further showed that the combination of etoposide and cisplatin (E/P) with statins had improved efficacy in a patient-derived xenograft (PDX) model derived from a relapsed patient with high GGPS1 expression. Our findings suggest that GGPS1 is a promising biomarker for predicting chemoresistance in SCLC and may be a potential indicator of sensitivity to statin combination therapy in chemoresistant SCLC.

We herein present an extremely rare case of coexisting NET and NEC of the whole pancreas with hepatoid differentiation. Due to a remarkable response to chemotherapy, conversion surgery was performed. However, early recurrence of liver metastases accompanied by a rapid increase in serum AFP levels occurred, and the prognosis was poor. Pancreatic HC should be considered when encountering a bulky tumor of the pancreas with elevated serum AFP levels, and further case series and analysis are needed to determine the appropriate treatment strategy.

Based on these findings, it can be concluded that rBlmet not only has great potential to treat pancreatic cancer in the future but can also be used as an adjuvant to enhance the effectiveness of chemotherapeutic agents like etoposide.

P2, N=47, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026

P1, N=11, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

These findings suggest that Hcys accumulation and its metabolic enzymes play a crucial role in cellular senescence. The online version contains supplementary material available at 10.1007/s10616-025-00803-w.

P2, N=92, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026

The regimen consisted of platinum-based chemotherapeutic agents, including cisplatin and etoposide (PE), combined with intensity-modulated radiation therapy using the simultaneous integrated boost technique to optimize tumor targeting while sparing critical structures such as the optic nerve. This case highlights the efficacy of CCRT in achieving durable disease control and functional recovery in patients with advanced SNUC. These findings underscore the potential of precision radiotherapy techniques and multimodal strategies for managing this challenging malignancy.

Through FACS sorting of pure cell engulfing (CIC) populations, we could also show that engulfing cells have an enhanced etoposide resistance. These data suggest that SH3BGRL and cell engulfment are required for certain GOFs of mutant p53.

In our study; the prognosis of breast NEN patients was better than the literature data. Maybe the prognosis of patients evaluated as breast NEN according to the new classification is better than the older classification groups.

P2, N=160, Active, not recruiting, University of Arkansas | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P3, N=382, Active, not recruiting, University of Arkansas | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2025 --> Sep 2026

P2, N=63, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2027 --> Oct 2029 | Trial primary completion date: Jun 2025 --> Oct 2027

P2, N=90, Active, not recruiting, University of Arkansas | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2026

P1, N=15, Recruiting, AIDS Malignancy Consortium | Trial completion date: Aug 2027 --> Jul 2030 | Trial primary completion date: Jul 2025 --> Jul 2029 | Active, not recruiting --> Recruiting

In this study, we achieved more favorable outcomes than those in previous studies. Neoadjuvant chemotherapy, which included the ICE regimen, not only resulted in tumor shrinkage in eight of 12 cases but also demonstrated a good prognosis when tumor shrinkage was achieved. These findings suggest that neoadjuvant chemotherapy with the ICE regimen may be a promising approach for managing NF1-MPNST.

P2, N=60, Recruiting, AHS Cancer Control Alberta | Trial completion date: Dec 2026 --> Jul 2027 | Trial primary completion date: Aug 2026 --> Dec 2026

P2, N=30, Recruiting, University of Washington | Trial completion date: Sep 2030 --> Mar 2031 | Trial primary completion date: Sep 2025 --> Mar 2026

Docking-based virtual screening suggests that budesonide, sirolimus, cephaeline, etoposide, and staurosporine may target proteins upregulated in GBM and ODG, such as APOC, MTHFD2, and LPL, in addition to their actual targets. Particularly, sirolimus and protriptyline exhibited comparable binding affinities against MTHFD2 (-11.23 kcal/mol) and LPL (-7.45 kcal/mol), respectively, compared to their actual targets. The holistic network-based approach applied in this study may be advantageous in the illumination of these subtypes and may aid in the design of improved therapeutics in treatment of the studied gliomas.

P=N/A, N=71, Completed, AstraZeneca | Recruiting --> Completed | Trial completion date: Dec 2025 --> Jan 2025 | Trial primary completion date: Dec 2025 --> Jan 2025